Showing results (711-720 of 963) with videos related to

Sort By:
Pageof 97
Hepatology (Baltimore, Md.)|June 1, 2010
Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markersAlexander J V Thompson, Tin Nguyen, David Iser, et al.
Plos One|May 13, 2021
Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBVCalvin Q Pan, Ting-Tsung Chang, Si Hyun Bae, et al.
Plos One|April 25, 2013
Identification of hepatotropic viruses from plasma using deep sequencing: a next generation diagnostic toolJohn Law, Juan Jovel, Jordan Patterson, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease InhibitorLuzelena Caro, Larissa Wenning, Zifang Guo, et al.
Alimentary Pharmacology & Therapeutics|November 29, 2017
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3Z M Younossi, M Stepanova, I M Jacobson, et al.
Trials|July 18, 2018
Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trialA J Wade, J S Doyle, E Gane, et al.
The New England Journal of Medicine|November 10, 2025
A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis DTarik Asselah, Michael A Chattergoon, Alina Jucov, et al.
Clinical Otolaryngology : Official Journal of ENT-UK ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery|August 28, 2020
Management of new onset loss of sense of smell during the COVID-19 pandemic - BRS Consensus GuidelinesClaire Hopkins, Mikkel Alanin, Carl Philpott, et al.
Alimentary Pharmacology & Therapeutics|March 10, 2018
Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patientsW-L Chuang, J Jia, H L Y Chan, et al.
BMC Infectious Diseases|June 4, 2017
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover studyEdward J Gane, Edwin DeJesus, Ewa Janczewska, et al.
Pageof 97